Business Wire

CA-PATIENT-SAFETY

Share
Patient Safety Movement Foundation Urges Clinicians, Patient Advocates, Hospitals & Medical Technology Companies to Support Data Sharing as Part of the 2020 Federal Health IT Plan

Patient Safety Movement Foundation is urging clinicians, patient advocates, hospitals and medical technology companies to support Data Sharing as part of the 2020 Federal Health IT plan.

“One of the key ways to combat preventable patient deaths in hospitals is for companies to share their data in a HIPAA compliant manner instead of hoarding it for profit. The plan proposed by the Office of the National Coordinator for Health Information Technology will help create the personalized patient data superhighway we need to reduce and eliminate preventable deaths in our hospitals,” said Joe Kiani, Founder of the Patient Safety Movement and Founder, Chairman, and CEO of Masimo. “If we block patient data, no one can create algorithms that can warn clinicians of potential problems before they happen. We are already losing way too many people to medical errors in our hospitals each year, and we can’t delay this any longer.”

Several years ago, a young man named Rory Staunton died of Sepsis because of exactly this type of fragmented medical information system. “On Tuesday, my son Rory was playing basketball at a school gym, fell and cut himself. His teacher put a bandaid on it. He died 5 days later from Sepsis,” said Orlaith Staunton. “Despite having a high heart rate for his size as measured by a patient monitor at his pediatrician’s office and a high white blood cell count that was detected in the Emergency Department’s blood test machine, Rory was sent home because no one had all of the details of his problems and care. They couldn’t put the high heart rate and high white blood cell count together with the full story to realize he had Sepsis. Had we had data sharing allowing a complete view of his history and condition or the benefit of a predictive algorithm to track my son’s case when he was connected to various monitors and blood test machines, he would probably be alive today.”

Since the founding of the Patient Safety Movement, nearly 100 companies have signed the voluntary Open Data Pledge, including Baxter, Cerner, Dräger, Edwards Lifesciences, GE Healthcare, IBM, Masimo, Medtronic, Oracle, Philips and Zoll. Complete list below. For more information on how you can sign the Pledge, please visit www.patientsafetymovement.org . For more information regarding the 2020 Federal Health IT Plan, please visit https://www.healthit.gov/sites/default/files/page/2020-01/2020-2025FederalHealthIT%20StrategicPlan_0.pdf .

Companies that have signed the Patient Safety Movement Foundation Open Data Pledge (alphabetical order):

AccuHealth Group

Admetsys

AirStrip

Ambient Clinical

Baxter

BD Intelliport (formerly CRISI Medical Systems)

Bernoulli Health

Beterra Health

BIOIN SOLUCIONES SAS

Biovigil

BrainStem Biometrics

caresyntax, Inc.

Cercacor

Cerner

Cheetah Medical, Inc.

Clean Hands-Safe Hands

CNSystems Medizintechnik AG

Codonics

CrossChx

DebMed

Decisio Health

Deltex Medical

Doctella

Dräger

DynaLabs LLC

11 Health

EarlySense

eBroselow, LLC

Edwards LifeSciences

Forcare

FUJIFILM SonoSite, Inc.

GE Healthcare

Genomi-k

Hamilton Medical AG

Handtevy-Pediatric Emergency Standards, Inc.

Healthcentrix

Heartin Inc.

HeROScore

Hiteks

IBM Watson Health

ICUcare

Informs Inc.

Innara Health

Iradimed

Jvion

KnectIQ Inc.

Kolkin

LiDCO Group

LumiraDX USA Inc.

Magnamed Tecnologia Médica S/A.

Masimo

Mdoloris Medical Systems

Medi+Sign

Medical Simulation Corporation

MediSafe Inc

Medtronic

Mindray

Modulated Imaging

Monarch Medical Technologies

Neosim

NeurOptics

Oracle

Patient Valet

Pegwin

PeraHealth

PerceptiMed

Philips Healthcare

Phoenix Medical Systems Pvt. Ltd.

Pieces Technology

Pooyandegan Rah Saadat Co.,Ltd.

Rapid Healthcare

Redivus Health

RGP Healthcare

RightPatient

RPRD Diagnostics

SafeCare Group

SafeStart Medical

SenTec Inc.

Smiths Medical

Sotera Wireless

Stanley Healthcare

Stibo Systems

SurgiCount Medical

SwipeSense

Talis Clinical

ThermoMedics, Inc.

Triton Electronic Systems LTD

True Process

Vitalacy (FORMERLY Hygenix)

Welch Allyn (acquired by Hill-Rom)

West-Com Nurse Call Systems, Inc

ZOLL Medical

About Patient Safety Movement Foundation

Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit that offers free tools to help achieve ZERO preventable deaths from hospital errors. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO. Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. PSMF’s World Patient Safety, Science & Technology Summit brings together the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. Our Actionable Patient Safety Solutions (APSS) provide evidence-based processes to help hospitals eliminate errors. Our Open Data Pledge encourages healthcare technology companies to share the data for which their products are purchased. Visit patientsafetymovement.org.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye